Also, combined targeting of the mTOR pathway and the mitotic checkpoint protein aurora kinase A, using rapamycin + MLN8237, synergistically reduced uLMS cell growth in vitro, as well as tumor growth in an in vivo model [61]. This evidence concerns the gene MTOR and neoplasm.